MGL is able to distinguish healthy tissue from tumor through its specific recognition of Tn antigen. In vitro studies, using CRC cell lines, showed an association between MGL ligand expression and the presence of BRAFV600E, suggesting a model in which activating BRAF mutations, and possibly other oncogenic alterations that activate the MAPK pathway, lead to an altered tumor cell glycosylation profile and enhanced expression of MGL ligands [48]. This evidence concerns the gene BRAF and neoplasm.